Seattle Genetics Inc. (SGEN)
-NasdaqGS 34.95 
0.40(1.13%) May 24, 4:00PM EDT|After Hours
:
34.96 0.01 (0.02%) May 24, 4:35PM EDT
| Prev Close: | 35.35 |
|---|
| Open: | 34.93 |
|---|
| Bid: | N/A |
|---|
| Ask: | 35.30 x 500 |
|---|
| 1y Target Est: | 32.42 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 34.57 - 35.40 |
|---|
| 52wk Range: | 19.03 - 39.00 |
|---|
| Volume: | 545,358 |
|---|
| Avg Vol (3m): | 795,872 |
|---|
| Market Cap: | 4.24B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SEATTLE GENETICS INC /WA Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 22)
- Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealedat Seeking Alpha(Wed, May 22)
- Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AMat Seeking Alpha(Tue, May 21)
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Playersat Motley Fool(Sun, May 19)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Thu, May 16)
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- SEATTLE GENETICS INC /WA FinancialsEDGAR Online Financials(Wed, May 15)
- Seattle Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- FDA accepts Seattle Genetics Adcetris applicationAP(Tue, May 14)
- Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDABusiness Wire(Tue, May 14)
- Companies Invest in Antibodies That Fight Tumorsat Motley Fool(Mon, May 13)
- These 4 Stocks Saw Trading Price Swings This Past Week Post Earningsat Wall St. Cheat Sheet(Sat, May 11)
- Seattle Genetics to Present at Upcoming Investor ConferencesBusiness Wire(Thu, May 9)
- The True Value Of Seattle Geneticsat Seeking Alpha(Thu, May 9)
- Narrower-than-Expected Loss at Seattle GeneticsZacks(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.49 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.82 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S.
View More